anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the technical field of carbon medicine synthesis, and discloses a method for synthesizing  11  C-choline, which comprises the following steps: s101, dissolving a lithium aluminum hydride LiAlH  4 /tetrahydrofuran THF solution in tetrahydrofuran THF to obtain a first intermediate, and filling the first intermediate into a reaction bottle. S102, the  11 C-CO 2  produced in advance of the accelerator is injected into a reaction bottle, the reaction bottle is bubbled, and  11 C-CO 2  is reacted with lithium aluminum hydride LiAlH  4  to obtain a second intermediate. And S103, introducing nitrogen into the second intermediate, and preparing a third intermediate by heating up and evaporating, reducing the nitrogen flow, cooling, distilling, increasing the nitrogen flow and stopping heating. S104, the third intermediate reacts with N.N-dimethylethanolamine precursor C18 column and CM column, and the finished product is prepared through washing and eluting. Avoiding reaction interference with N.N-dimethylethanolamine precursor, leading  11 C-CH 3  I to have higher purity and improving  11  C-choline yield. Also disclosed is a device for synthesizing  11  C-choline, synthesizing  11  C-choline in high yield, and a use of  11  C-choline for PET/CT imaging medicaments.
Keloids are characterized by fibroblast hyperproliferation and excessive accumulation of extracellular matrix (ECM) and are a major global health care burden among cutaneous diseases. However, the function of long noncoding RNA (lncRNA)-mediated ECM remodeling during the pathogenesis of keloids is still unclear. Herein, we identified a long noncoding transcript, namely, lymphocyte-specific protein 1 pseudogene 5 (LSP1P5), that modulates ECM component deposition in keloids. First, high-throughput transcriptome analysis showed that LSP1P5 was selectively upregulated in keloids and correlated with more severe disease in a clinical keloid cohort. Therapeutically, the attenuation of LSP1P5 significantly decreased the expression of ECM markers (COL1, COL3, and FN1) both in vitro and in vivo. Intriguingly, an antifibrotic gene, CCAAT enhancer binding protein alpha (CEBPA), is a functional downstream candidate of LSP1P5. Mechanistically, LSP1P5 represses CEBPA expression by hijacking Suppressor of Zeste 12 to the promoter of CEBPA, thereby enhancing the polycomb repressive complex 2-mediated H3K27me3 and changing the chromosomal opening status of CEBPA. Taken together, these findings indicate that targeting LSP1P5 abrogates fibrosis in keloids through epigenetic regulation of CEBPA, revealing a novel antifibrotic therapeutic strategy that bridges our current understanding of lncRNA regulation, histone modification and ECM remodeling in keloids.
The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
Study 6 (NCT#00428597) was a multi-center, international, randomized, double-blind, placebo-controlled study of single-agent SUTENT conducted in patients with unresectable pNET. Patients were required to have documented RECIST-defined disease progression within the prior 12 months and were randomized (1:1) to receive either 37.5 mg SUTENT (N=86) or placebo (N=85) once daily without a scheduled off-treatment period. The primary objective was to compare PFS in patients receiving SUTENT versus patients receiving placebo. Other endpoints included OS, ORR, and safety. Use of somatostatin analogs was allowed in the study.

Demographics were comparable between the SUTENT and placebo groups. Additionally, 49% of SUTENT patients had nonfunctioning tumors vs 52% of placebo patients, and 92% patients in both arms had liver metastases. A total of 66% of SUTENT patients received prior systemic therapy compared with 72% of placebo patients and 35% of SUTENT patients had received somatostatin analogs compared with 38% of placebo patients. Patients were treated until disease progression or withdrawal from the study. Upon disease progression or study closure, patients were offered access to SUTENT in a separate extension study.

As recommended by the Independent Data Monitoring Committee, the study was terminated prematurely prior to the prespecified interim analysis. This may have led to an overestimate of the magnitude of PFS effect. A clinically significant improvement for SUTENT over placebo in PFS was seen by both investigator and independent assessment. A hazard ratio favoring SUTENT was observed in all subgroups of baseline characteristics evaluated. OS data were not mature at the time of the analysis. There were 9 deaths in the SUTENT arm and 21 deaths in the placebo arm. A statistically significant difference in ORR favoring SUTENT over placebo was observed. Efficacy results are summarized in Table 15 and the Kaplan-Meier curve for PFS is in Figure 4.

Figure 4. Kaplan-Meier Curve of PFS in the pNET Study 6

Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumors.
The objective is to characterize differentially expressed proteins (DEPs) in Guillain-Barré Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) through high-throughput analysis. Sera from 11 healthy controls (HCs), 21 GBS and 19 CIDP patients were subjected to Olink Proteomics Analysis. In the comparison between CIDP and GBS groups, up-regulation of ITM2A and down-regulation of NTF4 were observed. Comparing GBS with HCs revealed 18 up-regulated and 4 down-regulated proteins. Comparing CIDP with the HCs identified 15 up-regulated and 4 down-regulated proteins. Additionally, the correlation between clinical characteristics and DEPs were uncovered. In conclusion, the DEPs have significant potential to advance our understanding of the pathogenesis in these debilitating neurological disorders.
This invention provides novel truncation mutants of a phytochrome from the bacterium  Deinococcus radiodurans . When expressed either in bacteria or mammalian cells, these mutant phytochromes spontaneously incorporate biliverdin, a ubiquitous intermediate in heme catabolism, and become fluorescent in the infrared (IR) region. These phytochromes are the first genetically encoded labels that can be excited by far-red light and fluorescent in the true IR (>700 nm). If these mutants instead incorporate protoporphyrin IX, an intermediate in heme biosynthesis, illumination now generates significant amounts of singlet oxygen. Singlet oxygen is useful because it can be used to kill individual proteins or cells, detect long-range protein-protein interactions, or generate electron-microscopic contrast. The invention also relates to methods of making and using such proteins and protein variants.
BACKGROUND: The Eastern Mediterranean Region (EMR) faces numerous public health risks caused by biological, chemical, man-made, and natural hazards. This manuscript aimed to assess the multifaceted interventions and strategies used to strengthen the EMR's preparedness capacities to respond properly to current and upcoming health emergencies.
OBJECTIVE: To address these challenges, it is crucial to implement comprehensive and robust strategic risk assessments and health emergency preparedness frameworks. The World Health Organization (WHO) takes a risk-based approach, emphasizing the significance of all-hazards emergency management and the creation of national health risk profiles using the Strategic Toolkit for Assessing Risk (STAR). Furthermore, the International Health Regulations (IHR) Monitoring and Evaluation Framework (MEF) ensures continuous learning and capacity building among Member States, enhancing their ability to manage health emergencies effectively. Key components include State Party Annual Reporting (SPAR), Joint External Evaluation (JEE), After Action Review (AAR), Intra Action Review (IAR), and Simulation Exercises (SimEx). Moreover, initiatives like One Health, Emergency Care Systems, Safe Hospitals, and Public Health Emergency Operations Centers (PHEOCs) reinforce preparedness and response capacities. Risk communication and community engagement (RCCE) strategies play a pivotal role in disseminating timely information and fostering community resilience. Furthermore, the management of Chemical, Biological, and Radiological (CBRN) incidents remains a priority, necessitating collaboration between the public health and security sectors. This comprehensive approach aims to strengthen health systems, reduce risks, and improve emergency response capabilities throughout the EMR, thereby promoting global health security and resilience.
CONCLUSION: The EMR is addressing public health challenges through frameworks like IHR-MEF, and RCCE. It is strengthening emergency care systems, ensuring safe hospitals, and establishing PHEOCs. Proactive measures to address CBRN events and collaboration are enhancing resilience. The inclusion of the One Health approach underscores the EMR's holistic strategy to address the health threats at the human-animal-environment interface. This demonstrates the EMR's commitment to global health security.
Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported in a small number of patients treated with somatropin. Symptoms usually occurred within 8 weeks after the initiation of somatropin. In all reported cases, IH-associated signs and symptoms resolved rapidly after cessation of therapy or a reduction of the somatropin dose. To exclude preexisting papilledema, perform fundoscopic examination before initiating treatment with SKYTROFA, and reassess periodically thereafter. If papilledema is observed by fundoscopy, stop somatropin treatment. If somatropin-induced IH is confirmed, restart treatment with SKYTROFA at a lower dose after IH-associated signs and symptoms have resolved.
PURPOSE:To prepare an attenuated live mumps vaccine having strong immunogenecity and effective to the prevention of mumps, by the acclimatizing subculture of novel mumps virus in a specific living cell. CONSTITUTION:Attenuated live vaccine is prepared by the acclimatized subculture of a wild mumps virus in a living cell selected from the cells of birds (e.g. amnion of grown chicken egg, chorioallantois of grown chicken egg, fibrocyte of chicken embrio, etc.) and human diploid cell (e.g. WI-38 starin cell, MRC-5 strain cell, etc.). The virus is a newly separated wild mumps virus having strong activity. The process enables the attenuation of the virus without lowering its strong immunogenecity.
This group includes patients who underwent zero-fluoroscopy radiofrequency catheter ablation (RFCA) for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) approach. The catheter was inserted through the median cubital vein or basilic vein, navigating through the axillary vein, subclavian vein, and brachiocephalic vein to reach the SVC. The ablation procedure was performed under conscious sedation and local infiltration anesthesia, with a large-tip electrode catheter used for mapping and ablation guided by the EnSite NavX system. The ablation parameters were set at 40 W power and 50°C temperature.
Precision tinted lenses available from Cerium Technologies (TM) which will be individually determined as being sub-optimal to alleviate visual stress symptoms. This colour will be as similar to the 'experimental' colour as possible and will not be aversive to the participant. To be worn for a minimum of 10 weeks for concentrated tasks.
Unilateral visual neglect from right hemisphere stroke is a condition that reduces a person's ability to attend to and process stimuli in one half, mostly left side, of their environment. This perceptual processing deficit can negatively affect individuals' daily living which in turn reduces functional independence. Music has been used as a therapeutic tool in a variety of settings to promote cognitive functions. In particular, music has been used to improve attention in the left sides for patients with visual neglect. Musical Neglect Training (MNT) has been developed for patients with visual neglect to improve attention in the left side.

The purpose of this study was to examine the immediate and longer-lasting effect of Musical Neglect Training (MNT) on unilateral visual neglect. A single-subject design was used, as participants served as their own control. Two individuals participated in this study. Participants underwent six individual MNT sessions. MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field. Two standardized assessments (Albert's and Line Bisection Test) were used. The assessments were administered immediately before and after each of the 6 MNT sessions to assess the immediate effect of MNT. Moreover, follow-up testing was done one week after their 6th session to examine the longer-lasting effects of MNT. Paired t-test was used to examine the immediate effect, and both participants showed significant improvement with Albert's Test in immediate effect.
The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
PURPOSE:A composition useful for protecting the skin, etc., stable to decomposition, preservable and usable stably for a long period, having no toxic action, obtained by blending an aqueous solution of a protein hydrolyzate with a specific ratio of propylene glycol as an antiseptic and antimicrobial agent. CONSTITUTION:An aqueous solution of protein hydrolyzate having about 500- about 5,000mol.wt. is blended with >=15wt%, preferably >=30wt% (especially 70wt%) calculated as content of a total composition propylene glycol. The content of the protein hydrolyzate in the composition is 10-60wt%, generally 20- 60wt%. A hydrolyzate obtained by hydrolyzing an animal protein such as collagen, casein, gelatin, etc. or a vegetable protein such as soybean protein, etc. with an acid or an alkali, or by enzymatic hydrolysis using a protease, is used as the protein hydrolyzate, and a hydrolyzate of particularly an animal protein, especially of collagen protein is preferable.
A novel growth factor (BTC-CG) was purified from the conditioned medium of pancreatic beta tumor cells initially derived from transgenic mice (RIP1-Tag2). The purification scheme included BioRex 70 chromatography, phenyl-Sepharose chromatography, TSL-GEL heparin FPLC and C4 reverse phase HPLC. The peptide also stimulated proliferation of bovine smooth muscle cells. It was not inactivated by boiling, by 10 mM dithiothreitol or by exposure to 1M acetic acid. Biological activity of BTC-GF was recovered from a single band of protein which had a molecular weight of 32,000 on SDS-PAGE. The partial N-terminal amino acid sequence of this protein from BTC-3 and BTC-J10 cells was determined with an ABI 470A protein sequencer to be: <IMAGE>
The present invention adopts antitumor antibiotic lidamycin (LDM) as 'warhead' medicine coupled with a Fab'segment of a monoclonal antibody (single antibody). An anti-IV type collagenase single antibody 3D6 and an anti-human body liver cancer BEL-7402 cell single antibody 3A5Fab'segment are obtained by an appropriate method. N-hydroxy succinimide group-in-(N-maleimido) benzoic acid ester can be used as a coupling agent. Two kinds of single antibody Fab'segments are respectively coupled with the lidamycin, and two coupling substances Fab'-LDM can be obtained. The molecular weight of the coupling substances is measured as 65kDa by a polyacrylamide gel electrophoresis method, and the inhibiting action of KB and BEL-7402 cells cultured in vitro for the coupling substances is detected by a clone formation method. The result shows that the coupling substances have strong inhibiting action to target cells KB. Liver cancer 22 and colon cancer 26 can be used for in vivo experiment. The inhibiting action of Fab'-LDM coupling substances to liver cancer and colon cancer is obviously stronger than that of the lidamycin of the same dose. The present invention can determine that the lidamycin can be used as the 'warhead' medicine for preparing antitumor single antibody medicine coupling substances of miniaturization and high efficiency.
BACKGROUND: Endoleaks are the most common complication after endovascular aneurysm repair (EVAR). Computed tomography angiography (CTA) is presently the golden standard for lifelong surveillance after EVAR. Several studies and meta-analyses have shown contrast-enhanced ultrasound (CEUS) to be a good alternative. The main goal of our study was to further validate the inclusion of CEUS in follow-up examination protocols for the systematic surveillance after EVAR.
METHODS: A retrospective analysis of patients who had received CEUS as part of their routine surveillance after EVAR at our center was conducted. Detection rate and classification of endoleak types were compared between available postinterventional CTA/magnetic resonance angiography and follow-up CEUS examinations. Last preinterventional CTAs before EVAR served as baselines with focus on potential cofactors such as age, body mass index, maximum aortic aneurysm diameters, endoleak orientation, and distance-to-surface influencing detection rates and classification.
RESULTS: In total, 101 patients were included in the analysis. Forty-four endoleaks (43.5% of cases) were detected by either initial CEUS or CTA, mostly type II (37.6% of the included patients). Initial CEUS showed an endoleak sensitivity of 91.2%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 84.6%. No covariate with an influence on the correct classification could be identified either for CEUS or CT.
CONCLUSIONS: CEUS should be considered a valid complementary method to CTA in the lifelong surveillance after EVAR. As type II endoleaks seem to be a common early-term, sometimes spontaneously resolving complication that can potentially be missed by CTA, we suggest combined follow-up protocols including CEUS in the early on postinterventional assessment.
This intervention group receives 16 sessions of CBT-based, individual psychotherapy using to the Unified Treatment Protocol for the treatment of emotional disorders by Barlow et al. (2011).
The Lower Quarter Y-Balance Test (YBT-LQ) is used to assess dynamic balance and functional symmetry in healthy adults, athletes, and those who are rehabilitating a lower extremity injury, and has good to excellent interrater reliability. Performing the YBT-LQ requires utilization of different neuromotor and postural control strategies in each direction of the test. The OPTIMAL theory of motor learning is a theoretical framework that has been shown to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task. These components of the OPTIMAL theory of motor learning have been demonstrated to enhance balance learning in several populations. There is also extensive literature on the effects of the individual components of the OPTIMAL theory of motor learning and some evidence that demonstrates the beneficial effects of the combined components on motor learning. However, to the authors knowledge, literature has not been published upon the effect of all three components of the OPTIMAL theory of motor learning on dynamic balance learning. Therefore, the purpose of this study is intended to determine if the OPTIMAL theory of motor learning will influence performance on the YBT-LQ.

Healthy participants aged 18 to 65 will be recruited for participation through word-of-mouth advertising. Inclusion criteria will include a passing score of \>35 degrees bilateral ankle dorsiflexion and an ability to balance on one leg. Upon signing the informed consent document from participants, height, weight, BMI, gender, age, and limb length will be recorded for data analysis. Participants will be randomly assigned to one of two groups: an OPTIMAL motor learning group or a control group. The intended experimental design will be a multigroup nonequivalent pretest-posttest control group for this study. Participants will attend two study visits separated by 2-14 days. A visit one baseline YBT-LQ pretest will be administered in a standardized fashion the same for both groups. During visit two, the OPTIMAL group will practice the YBT-LQ using OPTIMAL principles, while the control group practices the YBT-LQ using standard principles, then both groups will undergo a posttest YBT-LQ measurement. Primary outcome measures will be normalized composite scores of the YBT-LQ. Secondary outcome measures will be participant self-reported measures of perceived competence, task effort, level of autonomy, and externally focused attention during the task on a 0 to 10 Likert scale.
1346534 Stabilized doxycycline solutions PFIZER CORP 12 July 1972 [19 July 1971] 32683/72 Heading A5B Stable aqueous solutions of doxycycline and a magnesium compound also contain a non- ionic surface active agent and have a pH of 5 to 7. The doxycycline may be in the form of its hydrochloride, sulphate, ascorbate, lactate, isonicotinate, gentisinate, nitrate or glutamate. The magnesium compound may be magnesium chloride hexahydrate. The surface active agent may be polyoxyethylenated hydrogenated castor oil or polyoxymethylenated sorbitan oleate. The pH may be adjusted by addition of ethanolamine, citric acid, ammonium hydroxide or sodium hydroxide. The composition may also include an antioxidant, e.g. α-monothioclycerol, magnesium formaldehyde sulphoxeylate, sodium metabisulphite, sodium sulphite, sodium sulphide or thiosorbitol.
BACKGROUND: Cutaneous manifestations are frequently observed in end-stage kidney disease (ESKD) and affect the quality of life (QoL) of patients undergoing maintenance hemodialysis (HD). Even patients undergoing HD who frequently visit hospitals do not receive active dermatological care. The aims of this study were to assess the cutaneous manifestations of patients undergoing HD and investigate changes in their QoL before and after active treatment by dermatologists.
METHODS: A 12-week prospective study was conducted in two HD centers. Patients in one center received dermatological intervention, while patients in the other center received conservative management by a nephrologist. Patients scored their QoL using the Dermatology Life Quality Index (DLQI) and the Skindex-29 at the start of the study and 12 weeks later. Two matched groups were formed using propensity score matching. Simple and multiple linear regression analyses were used to identify associations between dermatological treatment and the improvement in QoL.
RESULTS: In total, 120 patients were included, of whom 65 and 55 were in the intervention and control groups, respectively. Approximately 93.8% of the patients had dermatological manifestations, with pallor and xerosis being the most common. Improvement in QoL, as assessed using the DLQI, was confirmed after 12 weeks in the overall population. However, active intervention by a dermatologist did not significantly improve QoL.
CONCLUSION: Patients treated with dermatological intervention by a dermatologist did not achieve greater improvements in QoL than control patients. Therefore, careful assessment of skin issues in patients with ESKD should be undertaken by nephrologists, and the best possible treatment should be administered.